Search Results

Cover Focus

Three Real-World Scenarios in Which a Minimally Invasive Approach Prevailed

In these cases, MIGS was a safer, effective alternative to traditional incisional surgery.

Arkadiy Yadgarov, MD

Case Files

A Patient With a Family History of Axenfeld-Rieger Syndrome and Glaucoma

Clinicians discuss how they would approach diagnosis and management for this teenager.

Steven R. Sarkisian Jr, MD; Lauren S. Blieden, MD; Abdelrahman M. Elhusseiny, MD, MSc; and Andrew R. Lee, MD

Cover Focus

Episcleral Angiography

Targeting the final frontier of aqueous outflow.

Osamah Saeedi, MD, MS, and Saige Oechsli, BS

Case Files

Off-Target After Multiple Interventions

Surgeons weigh the next steps for a patient with uncontrolled IOP who is intolerant of topical medications.

Steven R. Sarkisian Jr, MD; Ticiana De Francesco, MD; Alexandros Pappas, DO; Justin Spaulding, DO; and H. George Tanaka, MD

Case Files

Glaucoma in a Very Long Eye

Surgical planning in a high-stakes case.

Devesh K. Varma, MD, FRCSC; Victor Koh, MBBS, MMed(Ophth), MRCSEd, MSc, FAMS; Sarwat Salim, MD, FACS; Kateki Vinod, MD; and Chungkwon Yoo, MD, PhD

Evolving Strategies in Early- Stage Glaucoma Management

A focus on the complementary roles of selective laser trabeculoplasty and sustained-release drug delivery.

Inder Paul Singh, MD; Lorraine M. Provencher, MD; Emily M. Schehlein, MD; Manjool Shah, MD; Swarup Swaminathan, MD; and Zarmeena Vendal, MD

Procedural Pharmaceuticals in Glaucoma Management

Steven R. Sarkisian Jr, MD

IJC Recap: Procedural Pharmaceuticals, Stability of Arcuate Keratotomy, and Work-Life Balance

Innovation Journal Club explores recently published and presented data around innovations in eye care with a focus on how they might shape real-world practice.

Inder Paul Singh, MD

Case Files

To Treat or Not to Treat

The case of a glaucoma suspect with a family history of blindness from the disease.

Steven R. Sarkisian Jr, MD; James D. Brandt, MD; Bac T. Nguyen, MD; and Billy Pan, MD

In Memoriam

Remembering Murray Johnstone, MD

Patient Success Stories With iStent Infinite

If you only had one option at your disposal, what would you choose?

J. Morgan Micheletti, MD

Cover Focus

Standalone MIGS

Weighing the benefits and risks of surgical approaches.

Nathan M. Radcliffe, MD

The Effect of Microinvasive Glaucoma Surgery On Aqueous Homeostasis

Safe and Effective Glaucoma Management With iDose TR (Travoprost Intracameral Implant) 75 mcg

Continuous long-term prostaglandin analog therapy helps relieve a patient’s medication burden.

Mehul Nagarsheth, MD, and Helen Lahmann-Metcalfe (Supporting Author)

Case Files

A Persistent Steroid Response

A patient with a history of juvenile open-angle glaucoma is concerned her vision is deteriorating.

Steven R. Sarkisian Jr, MD; Jella An, MD, MBA; Eva DeVience, MD; and Lauren S. Blieden, MD

The Emergence of Breakthrough Procedural Pharmaceutical Therapies

Mark Gallardo; Courtney Bovee; and Savak Teymoorian

A Deep Dive on the iDose^® TR Phase 2b Trial

Sustained efficacy and safety data can help guide clinical decisions.

Inder Paul Singh, MD

Case Files

A Request to Discontinue Topical Therapy

The patient is on maximum tolerated medical therapy and has undergone multiple interventions.

Steven R. Sarkisian Jr, MD; Matthew Brink, MD; George R. Reiss, MD; and I. Paul Singh, MD

Is Standalone MIGS the Next Evolution in the Interventional Mindset?

Data demonstrating the safety and efficacy of standalone MIGS procedures allows surgeons to question whether “one more drop” is the right choice.

Steven R. Sarkisian Jr, MD, and Arkadiy Yadgarov, MD

Health Care

Is Glaucoma Policy Short-Sighted?

Redefining innovation to keep an eye on patient access.

Sara Riaz, MSc; Blake Oberfeld, MD; Hani El Helwe, MD; Henisk Falah, BS; and David Solá-Del Valle, MD